Dr. Jonathan D. Fish, M.D.
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
NY license 227830
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 20 payments worth $21,155 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $15,143 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $5,900 |
| Mesoblast, Inc. | $112 |
| Consulting Fee | $20,076 |
|---|---|
| Travel and Lodging | $890 |
| Food and Beverage | $189 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee | $7,088 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee CASGEVY · SICKLE CELL DISEASE/BETA THALESSEMIA | $7,088 |
| Alexion Pharmaceuticals, Inc. Dec 24, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $1,050 |
| Alexion Pharmaceuticals, Inc. Jan 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $1,000 |
| Alexion Pharmaceuticals, Inc. Oct 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $875 |
| Alexion Pharmaceuticals, Inc. Jul 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $750 |
| Alexion Pharmaceuticals, Inc. Apr 2, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $700 |
| Alexion Pharmaceuticals, Inc. Jun 24, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $525 |
| Alexion Pharmaceuticals, Inc. Apr 2, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $500 |
| Alexion Pharmaceuticals, Inc. Oct 22, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $500 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Dec 24, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $1,050 |
| Alexion Pharmaceuticals, Inc. Oct 22, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $500 |
| Alexion Pharmaceuticals, Inc. Oct 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $875 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee | $7,088 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Consulting Fee CASGEVY · SICKLE CELL DISEASE/BETA THALESSEMIA | $7,088 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Travel and Lodging CASGEVY · SICKLE CELL DISEASE/BETA THALESSEMIA · travel to BOSTON, MA · in-kind | $14.96 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $14.96 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Travel and Lodging CASGEVY · SICKLE CELL DISEASE/BETA THALESSEMIA · travel to BOSTON, MA · in-kind | $14.95 |
| Vertex Pharmaceuticals Incorporated Aug 6, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $14.95 |
| Vertex Pharmaceuticals Incorporated Jul 28, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $348 |
| Vertex Pharmaceuticals Incorporated Jul 27, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $482 |
| Alexion Pharmaceuticals, Inc. Jul 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $750 |
| Alexion Pharmaceuticals, Inc. Jun 24, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $525 |
| Alexion Pharmaceuticals, Inc. Apr 2, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $700 |
| Alexion Pharmaceuticals, Inc. Apr 2, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $500 |
| Alexion Pharmaceuticals, Inc. Jan 1, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.